Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma

  • Received : 2013.04.20
  • Accepted : 2013.09.30
  • Published : 2013.12.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 $mg/m^2/day$) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (${\geq}$grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.

Keywords

References

  1. Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, et al. : Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112 : 1139-1146, 2008 https://doi.org/10.1002/cncr.23167
  2. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. : Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12 : 259-266, 2001 https://doi.org/10.1023/A:1008382516636
  3. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. : Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma : a prospective GICNO study. J Clin Oncol 24 : 4746-4753, 2006 https://doi.org/10.1200/JCO.2006.06.3891
  4. Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D, et al. : Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer 101 : 2079-2085, 2004 https://doi.org/10.1002/cncr.20611
  5. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. : Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24 : 2707-2714, 2006 https://doi.org/10.1200/JCO.2005.04.3414
  6. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. : Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12 : 2013-2021, 1994 https://doi.org/10.1200/JCO.1994.12.10.2013
  7. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. : Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma : Long-Term Results of RTOG 9402. J Clin Oncol 31 : 337-343, 2013 https://doi.org/10.1200/JCO.2012.43.2674
  8. Chamberlain MC, Glantz MJ : CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol 89 : 231-238, 2008 https://doi.org/10.1007/s11060-008-9613-6
  9. Chamberlain MC, Johnston S : Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 115 : 1734-1743, 2009 https://doi.org/10.1002/cncr.24179
  10. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, et al. : Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19 : 2449-2455, 2001 https://doi.org/10.1200/JCO.2001.19.9.2449
  11. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, et al. : Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83 : 53-60, 2007 https://doi.org/10.1007/s11060-006-9302-2
  12. Ducray F, del Rio MS, Carpentier C, Psimaras D, Idbaih A, Dehais C, et al. : Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. J Neurooncol 101 : 457-462, 2010
  13. Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, et al. : A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro Oncol 12 : 500-507, 2009
  14. Gaya A, Rees J, Greenstein A, Stebbing J : The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28 : 115-120, 2002 https://doi.org/10.1053/ctrv.2002.0261
  15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-1280, 1990 https://doi.org/10.1200/JCO.1990.8.7.1277
  16. Macdonald DR, Gaspar LE, Cairncross JG : Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27 : 573-574, 1990 https://doi.org/10.1002/ana.410270519
  17. Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, et al. : Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92 : 57-63, 2009 https://doi.org/10.1007/s11060-008-9735-x
  18. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, et al. : A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma : an interim analysis. J Neurooncol 89 : 187-193, 2008 https://doi.org/10.1007/s11060-008-9603-8
  19. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al. : Phase I trial of temozolomide (CCRG 81045 : M&B 39831 : NSC 362856). Br J Cancer 65 : 287-291, 1992 https://doi.org/10.1038/bjc.1992.57
  20. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 : 510-522, 2010 https://doi.org/10.1016/j.ccr.2010.03.017
  21. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG : Salvage chemotherapy for oligodendroglioma. J Neurosurg 85 : 597-601, 1996 https://doi.org/10.3171/jns.1996.85.4.0597
  22. Pobereskin LH, Chadduck JB : Incidence of brain tumours in two English counties : a population based study. J Neurol Neurosurg Psychiatry 69 : 464-471, 2000 https://doi.org/10.1136/jnnp.69.4.464
  23. Reifenberger G, Louis DN : Oligodendroglioma : toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62 : 111-126, 2003 https://doi.org/10.1093/jnen/62.2.111
  24. Soffietti R, Ruda R, Bradac GB, Schiffer D : PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43 : 1066-1073, 1998 https://doi.org/10.1097/00006123-199811000-00035
  25. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T : Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas : a clinical efficacy trial. J Neurooncol 79 : 153-157, 2006 https://doi.org/10.1007/s11060-005-9020-1
  26. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. : Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma : long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31 : 344-350, 2013 https://doi.org/10.1200/JCO.2012.43.2229
  27. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. : Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas : a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 : 2715-2722, 2006 https://doi.org/10.1200/JCO.2005.04.6078
  28. van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, et al. : Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy : EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14 : 599-602, 2003 https://doi.org/10.1093/annonc/mdg157
  29. van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, et al. : Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51 : 1140-1145, 1998 https://doi.org/10.1212/WNL.51.4.1140
  30. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. : Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors : the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21 : 2525-2528, 2003 https://doi.org/10.1200/JCO.2003.12.015
  31. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009 https://doi.org/10.1056/NEJMoa0808710
  32. Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, et al. : Temozolomide chemotherapy in patients with recurrent malignant gliomas. J Korean Med Sci 21 : 739-744, 2006 https://doi.org/10.3346/jkms.2006.21.4.739
  33. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. : A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 : 588-593, 2000 https://doi.org/10.1054/bjoc.2000.1316
  34. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. : Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17 : 2762-2771, 1999 https://doi.org/10.1200/JCO.1999.17.9.2762

Cited by

  1. A rare case of oligoastrocytoma with atypical symptoms initially diagnosed as multiple sclerosis: A case report vol.4, pp.2, 2013, https://doi.org/10.3892/mco.2015.686
  2. Rechallenge temozolomide in glioma: A case series from India vol.54, pp.1, 2013, https://doi.org/10.4103/ijc.ijc_173_17
  3. The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01 vol.7, pp.2, 2013, https://doi.org/10.14791/btrt.2019.7.e42
  4. The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01 vol.7, pp.2, 2013, https://doi.org/10.14791/btrt.2019.7.e43
  5. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas vol.26, pp.4, 2013, https://doi.org/10.3390/molecules26041169
  6. Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme vol.13, pp.5, 2013, https://doi.org/10.3390/cancers13051013